Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.52 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.47 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.47 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.47 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.47 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.47 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.47 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256744 | 0.85 | ACACB (0.43) | GPR119 | |
| SCHEMBL3174661 | 0.84 | GPR119 (0.54) | GPR119 | |
| SCHEMBL20227205 | 0.84 | GPR119 (0.54) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL22156950 | 0.83 | GPR119 (0.53) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL29826104 | 0.83 | GPR119 (0.52) | GPR119NPC1ALDH1A1MAPTMAPK1 | |
| SCHEMBL17572116 | 0.82 | GPR119 (0.53) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL20137890 | 0.82 | GPR119 (0.53) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3258915 | 0.81 | GPR119 (0.54) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3255941 | 0.81 | GPR119 (0.52) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL27158018 | 0.81 | GPR119 (0.54) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | GPR119 2308/4885CACNB4 3028/4885CACNA1A 1918/4885 |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | GPR119 2308/4885CACNB4 3028/4885CACNA1A 1918/4885 |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | ABCB1, CYP3A5, CYP3A4 | GPR119 1804/4885CACNB4 3099/4885CACNA1A 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.